(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Manual for Picking the Ideal Wine Matching - 225 Years Ago, Audi's Rosemeyer Concept Was A Steampunk Supercar With A Massive Engine
- 3Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- 4Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
- 5Step by step instructions to Protect Your Retirement with Senior Protection.
- The Delight of Perusing: Book Proposals for Each Class
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- Vote In favor of Your Favored Pizza Cover
- Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- Barry Manilow to have surgery for early-stage lung cancer and postpones January concerts
- Step by step instructions to Pick the Right Web-based Degree Program
- CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms
- Fundamental Monetary Guidance for Going into Business
- Well known Tea Brands for Each Tea Sweetheart
